CO135 Hospitalization and Exacerbation Estimates of Efgartigimod Vs. Conventional Therapy in Generalized Myasthenia Gravis Patients: A Post-Hoc Analysis of the Phase 3 ADAPT Study
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.230
https://www.valueinhealthjournal.com/article/S1098-3015(22)00431-4/fulltext
Title :
CO135 Hospitalization and Exacerbation Estimates of Efgartigimod Vs. Conventional Therapy in Generalized Myasthenia Gravis Patients: A Post-Hoc Analysis of the Phase 3 ADAPT Study
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00431-4&doi=10.1016/j.jval.2022.04.230
First page :
Section Title :
Open access? :
No
Section Order :
10198